Last checked at 5 Sep 2018 07:00
5 September 2018
Avacta Group plc
("Avacta", the "Group" or the "Company")
Notice of Results
Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, will announce its financial results for the year ended 31 July 2018 on Tuesday, 2 October 2018.
An analyst briefing given by Alastair Smith, Chief Executive Officer and Tony Gardiner, Chief Financial Officer, will be held at 09.30 hrs on Tuesday, 2 October 2018 at finnCap's offices, 60 New Broad St, London EC2M 1JJ.
- Ends -
For further information from Avacta Group plc, please contact:
Avacta Group plc Alastair Smith, Chief Executive Officer Tony Gardiner, Chief Financial Officer
| Tel: +44 (0) 844 414 0452 www.avacta.com
|
finnCap Ltd Geoff Nash / Giles Rolls - Nominated Adviser Tim Redfern / Nikita Jain - Corporate Broking
WG Partners Nigel Birks / Nigel Barnes David Wilson / Claes Spang
| Tel: +44 (0) 207 220 0500 www.finncap.com
Tel: +44 (0) 203 705 9318 Tel: +44 (0) 203 705 9317 www.wgpartners.co.uk
|
Zyme Communications (Trade and Regional Media) Katie Odgaard
Yellow Jersey (Financial Media and IR) Sarah Hollins | Tel: +44 (0)7787 502 947 katie.odgaard@zymecommunications.com
Tel: +44 (0)7764 947137 avacta@yellowjerseypr.com
|
About Avacta Group plc (www.avacta.com)
Avacta's principal focus is on its proprietary Affimer® technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development.
Antibodies dominate markets worth in excess of $100bn despite their shortcomings. Affimer technology has been designed to address many of these negative performance issues, principally; the time taken to generate new antibodies, the reliance on an animal's immune response, poor specificity in many cases, and batch to batch variability. Affimer technology is based on a small protein that can be quickly generated to bind with high specificity and affinity to a wide range of protein targets.
Avacta has a pre-clinical biotech development programme with an in-house focus on immuno-oncology and bleeding disorders as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer reagents through licensing to developers of life sciences research tools and diagnostics.